Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus

(2015) Thomas Wilke et al.   Cardiovascular Diabetology

Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study

(2015) A Hochhaus et al.   LEUKEMIA

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

(2014) Carlo Gambacorti-Passerini et al.   AMERICAN JOURNAL OF HEMATOLOGY

Application of systematic coronary risk evaluation chart to identify chronic myeloid leukemia patients at risk of cardiovascular diseases during nilotinib treatment

(2014) Massimo Breccia et al.   ANNALS OF HEMATOLOGY

Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily

(2014) T. P. Hughes et al.   HAEMATOLOGICA

Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities

(2013) P. Jain et al.   BLOOD

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib

(2013) T. P. Hughes et al.   BLOOD

Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase

(2013) A. Hochhaus et al.   BLOOD

Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION)

(2013) E. Jabbour et al.   BLOOD

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

(2013) Neil J. Stone et al.   CIRCULATION

Deep Molecular Response in Chronic Myeloid Leukemia: The New Goal of Therapy?

(2013) F.-X. Mahon et al.   CLINICAL CANCER RESEARCH

Achieving deeper molecular response is associated with a better clinical outcome in chronic myeloid leukemia patients on imatinib front-line therapy

(2013) G. Etienne et al.   HAEMATOLOGICA

Prevalence of Coronary Atherosclerosis in Asymptomatic Healthy Subjects: An Intravascular Ultrasound Study of Donor Hearts

(2013) Min-Seok Kim et al.   Journal of Atherosclerosis and Thrombosis

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IV

(2013) Rüdiger Hehlmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Peripheral artery occlusive disease in chronic phase chronic myeloid leukemia patients treated with nilotinib or imatinib

(2013) T D Kim et al.   LEUKEMIA

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis

(2013) F J Giles et al.   LEUKEMIA

Longitudinal Effects of a Decade of Aging on Carotid Artery Stiffness

(2013) Adam D. Gepner et al.   STROKE

Pulmonary Arterial Hypertension in Patients Treated by Dasatinib

(2012) David Montani et al.   CIRCULATION

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)

(2012) et al.   EUROPEAN HEART JOURNAL

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)

(2012) B Hanfstein et al.   LEUKEMIA

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up

(2012) R A Larson et al.   LEUKEMIA

Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

(2011) David Marin et al.   JOURNAL OF CLINICAL ONCOLOGY

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

(2011) Hagop M Kantarjian et al.   LANCET ONCOLOGY

Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib

(2010) A. Haouala et al.   BLOOD

Standards of Medical Care in Diabetes--2011

(2010)   DIABETES CARE

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

(2010) Giuseppe Saglio et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chronic myeloid leukemia patients with the e13a2 BCR-ABL fusion transcript have inferior responses to imatinib compared to patients with the e14a2 transcript

(2009) C. M. Lucas et al.   HAEMATOLOGICA

General Cardiovascular Risk Profile for Use in Primary Care

(2008) Ralph B. D’Agostino et al.   CIRCULATION